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Abstract
The human telomerase reverse transcriptase (hTERT)
is an essential component of the holoenzyme complex
that adds telomeric repeats to the ends of chromo-
somes. The hTERT transcript has been shown to have
two deletion type alternative splicing sites. One
deletion site induces the A-deletion variant, lacking
36 bp from exon 6, and the other induces the B-deletion
variant, lacking 182 bp from exons 7 and 8. Here,
we identified a novel deletion variant of the hTERT
transcript in hepatocellular carcinoma cell lines. The
deleted transcript was characterized by an in-frame
deletion of 189 bp, spanning nucleotides 2710 to 2898,
corresponding to the complete loss of exon 11
(G-deletion). The region lacking in the G-deletion lies
within RT motifs D and E, suggesting that it is missing
conserved residues from the catalytic core of the
protein. Both G- and A-deletion variants were occa-
sionally detected, but the B-deletion variant was
frequently observed. Our results may provide impor-
tant information for more detailed studies on the
regulation of telomerase activity.
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Introduction
Pre-mRNA splicing is a fundamental biological process
involved in the expression of genes, and up to a third of
human genes are thought to be alternatively spliced [1,2].
General alternative splicing takes place in variant proteins
and expression patterns as products of different genes.
Recently, Serine–Arginine (SR) proteins have been shown
to play a role in constitutive and alternative splicing, and the
characters and functions of SR proteins have now been
extensively investigated [3,4]. Some alternatively spliced
variants (ASVs) have been associated with a subset of
human diseases [5–8]; however, the pathological impor-
tance of ASVs in most human diseases is still uncertain.
Human telomerase reverse transcriptase (hTERT)
[9–11], which has two deletion-type ASVs [12,13], is the
protein component for telomerase. Telomerase adds DNA
repeats to the ends of chromosomes [14], and the enzyme
telomerase plays a crucial role in cellular proliferation, devel-
opment, and tumorigenesis [15,16]. The hTERT gene consists
of 16 exons and the transcript is about 4.0 kb long [17]. The
protein has a molecular mass of 127 kDa and contains a
telomerase-specific motif and seven reverse transcriptase
(RT) motifs [17,18]. The deletion-type ASVs are a- and h-
deletion types [19–21]. The a-deletion ASV lacks 36 nucleo-
tides from exon 6 including motif A, and the h-deletion ASV
lacks 182 nucleotides from exons 7 and 8, including motif BV.
The a-deletion ASV mRNA has occasionally been detected,
whereas the h-deletion mRNA is frequently observed irre-
spective of the telomerase activity [19–21].
We have now identified a novel ASV of hTERT mRNA. The
ASV identified lacks the entire exon 11, and the protein
encoded by this ASV was conserved with no frameshift muta-
tion. Although ASVs are transcripts from a single gene, it is
important to discriminate the full-length isoform from ASVs.
The aim of the present investigation was to demonstrate
evidence of a novel ASV of hTERT gene expression in hep-
atocellular carcinoma (HCC) cell lines. Here, we developed a
polymerase chain reaction (PCR)–based specific assay for the
quantification of alternatively spliced hTERT expression.
Materials and Methods
Total RNA was extracted from three cell lines [Japan Health
Science Foundation (HSRRB), Osaka, Japan] derived from
HCC, Huh 7, HLE, and Huh 6–clone 5, and from two normal cell
lines (HSRRB) LI 90 (derived from normal Ito cells) and HUV-
EC-C (derived from normal endothelial cells) (Table 1) using
the RNAzolB reagent (Sawady, Shinjuku, Japan) following the
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manufacturer’s instructions. The final RNA preparations
were resuspended in diethylpyrocarbonate-treated water
and quantified by absorbance analysis at 260 nm. Comple-
mentary DNA (cDNA) was prepared by incubating DNase-
treated total RNA (1.0 Ag) with M-MLV RT (Invitrogen,
Carlsbad, CA, USA) in the presence of random primers.
ASV Identification
The primer set for the amplification of an hTERT mRNA
was designed according to GenBank AF128894, using
forward primers at the exon 10 region (5V-CTG CAG GAG
ACC AGC CCG C-3V) and reverse primers at the exon 13
region (5V-ACA CCG TCT GGA GGC TGT TCA-3V). The
reaction parameters were 95jC for 30 seconds, 60jC for
40 seconds, and 72jC for 30 seconds for 45 cycles,
followed by a 10-minute extension at 72jC using AmpliTaq
Gold DNA polymerase (PE Applied Biosystems, Foster City,
CA). Half of the PCR product was separated by electro-
phoresis in TBE buffer in a 3.0% agarose gel, stained with
ethidium bromide, and then detected with ultraviolet light
(Figure 1a).
The PCR products of hTERT were purified using a High
Pure PCR Product Purification Kit (Roche Molecular Bio-
chemicals Diagnostics, Indianapolis, IN), cloned into a
pCR2.1 vector (Invitrogen) and then sequenced using a
BigDye Terminator Cycle Sequencing Ready Reaction Kit
(PE Applied Biosystems) with an ABI PRISM 3100 Genetic
Analyzer (PE Applied Biosystems). Finally, the sequence
was compared with the full-length hTERT mRNA sequence
(Figure 1b).
Specific Quantitative System (RT Real-Time PCR)
The real-time PCR reaction mixture was prepared using a
TaqMan PCR Core Reagents Kit (PE Applied Biosystems).
The primers and probes to amplify the mRNA of the full-
length isoform and ASVs mRNA are shown in Table 2. The
real-time PCR reaction was performed for 55 cycles (95jC
for 30 seconds, 60jC for 45 seconds, 72jC for 30 seconds)
Figure 1. Alternative splicing of hTERT mRNA. (a) RT-PCR products of the hTERT gene spanning exons 10 to 13. An obvious shorter signal (*arrow) was
observed in the HLE sample. Huh 6, Huh 6–clone 5 cell line; HLE, HLE cell line; DNA, genomic DNA; Nc, negative control (RNase-free water); M, molecular weight
markers uX174 DNA/HinfI digest. (b) Sequence analysis of the transcript bearing the deletion of exon 11 of the hTERT gene. The sequence in (a) shows the in-
frame deletion spanning codons 904 to 966, corresponding to the complete loss of exon 11. An arginine-to-serine (Arg!Ser) transition is revealed at codon 903.
Table 1. Description of Cell Lines in this Study.
Cell lines Source JCRB number Establisher
Huh 6–clone 5 Well-differentiated hepatoma JCRB0401 I. Doi, J. Sato
Huh 7 Differentiated hepatoma JCRB0403 H. Nakabayashi, J. Sato
HLE Nondifferentiated hepatoma JCBR0404 I. Doi, J. Sato
LI 90 Normal Ito cell JCBR0160 K. Murakami, et al.
HUV-EC-C Normal endothelial cell IFO50271 H. Hoshi
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using a real-time PCR system (ABI PRISM 7700 Sequence
Detection System; PE Applied Biosystems).
To prepare standard RNA for the quantification, PCR
products were cloned into a pBluescript vector (Stratagene,
La Jolla, CA) and standard RNA was synthesized using T7
RNA polymerase and purified by RNAzolB and DNase I
(TaKaRa, Shiga, Japan) treatment.
Quantification of the mRNA samples was carried out by
relating the PCR threshold cycle obtained from the cell line
samples to the amplicon-specific standard curves. Serial
dilution of standard RNA was carried out in duplicate from
107 copies to 102 copies and used in triplicate RT real-time
PCR reactions. The mRNA expression levels are pre-
sented as the mRNA copy number per microgram of total
RNA [22].
Telomerase Activity
The telomerase activities of all cells were assessed
using a TRAP-eze Kit (Intergen, New York, NY) with a
Cy-5– labeled TS primer as described elsewhere [23,24].
Results
Identification of a Novel ASV of hTERT
The PCR mixture presented two bands on electrophore-
sis (Figure 1a). The sizes of these PCR products were
655 bp (no-deletion isoform) and 466 bp. The sequence
of the 466-bp product lacked 189 bp from the entire exon 11
(g-deletion; Figure 1b). For the g-deletion ASV, longer cDNA
were sequenced based on 5V and 3V rapid amplification of
cDNA ends (RACE) with long-distance PCR. The protein
encoded by the novel g-deletion ASV mRNA was 63aa
shorter than the full-length isoform. Amino acid sequences
without the missing region were conserved because no
frameshift mutation was observed.
To verify whether the exon deletion observed in our
samples was caused by genomic hTERT alteration, we
amplified the region of the hTERT genomic DNA that
included the splicing site of exon 11. Single-strand confor-
mation polymorphism (SSPC) analysis of exon 11 did not
demonstrate germline mutations responsible for the deletion
Table 2. Primers and Probes for Quantification of hTERT mRNA.
Primers and probes Positions
ex6-F primer 5V-ATG TGA CGG GCG CGT ACG A-3V Exon 6, nt 2135–2154
Adel-F primer 5V-CTG AGC TGT ACT TTG TCA AGG ACA GG-3V Exon 5, nt 2111–2130; exon 6, nt 2167–2172
ex11-R primer 5V-GGA AGT TCA CCA CTG TCT TCC GC-3V Exon 11, nt 2699–2721
Gdel-R primer 5V-CTT CCT CAG CTA TGC CCGGAC CT-3V Exon 10, nt 2646–2654; exon 12, nt 2843–2856
ex7 probe 5V-CCT GCA GGA GAC CAG CCC GCT GAG G-3V Exon 7, nt 2337–2361
Bdel probe 5V-CTT CAA GAG CCA CGT CCT ACG TCC AGT GCC-3V Exon 6, nt 2274–2286; exon 9, nt 2369–2385
α-deletion β-deletion γ-deletion
ex6-F ex7-probe ex11-R
4 5 6 7 8 9 10 11 12 13
Bdel-probe
Adel-F Gdel-R
no-deletion 588 bp
α-deletion 577 bp
β-deletion 407 bp
γ-deletion 534 bp
αβ-deletion 395 bp
αγ-deletion 522 bp
βγ-deletion 352 bp
αβγ-deletion 340 bp
Figure 2. Theoretically, alternative splicing of the hTERT transcript may lead to many isoforms. The a site causes a 36-base deletion resulting in a no-frameshift
mutation, and the b splice site results in a 182-base deletion resulting in a nonsense mutation. The c splice site induces a 189-base deletion resulting in a
no-frameshift mutation. The size of the PCR products produced by each primer set depends upon the alternative splicing of the hTERT transcript in the samples.
The Adel-F and ex6-F primers were forward primers, and ex11-R and Gdel-R were reverse primers.
G-Deletion Variant of Human Telomerase Reverse Transcriptase Gene Hisatomi et al. 195
Neoplasia . Vol. 5, No. 3, 2003
(data not shown). The possibility that the deleted transcript
could have resulted from PCR false priming or other artifacts
was excluded because triplicate experiments based on inde-
pendent RNA extractions and cDNA preparations yielded
consistent results.
Here, we have identified a novel ASV, g-deletion ASV.
The sequence was compared with nonredundant sequences
in GenBank, and no identical sequences were found. The
sequence of the g-deletion ASV was submitted to GenBank
(access no. AB085628).
Estimation of hTERT Expression
Theoretically, alternative splicing of the hTERT transcript
may lead to eight isoforms, as illustrated in Figure 2. The
a-deletion ASV, g-deletion ASV, and (an ASV combination of
these) the ag deletion ASV were characterized by in-frame
deletion, whereas the h-deletion ASV, ah deletion ASV, hg
deletion ASV, and ahg deletion ASV were characterized by
out-of-frame deletion, followed by premature termination. All
the ASVs were observed in this study.
The results of the relative levels are shown in Table 3. No
hTERT mRNA were detected in LI 90 and HUV-EC-C cells.
In the three cell lines with hTERT signals, the average
intensities of the no-deletion isoform, a-deletion, h-deletion,
g-deletion, ah deletion, ag deletion, hg deletion, and ahg
deletion ASVs were 22%, 4%, 64%, 1%, 7%, < 1%, 2%, and
< 1%, respectively. The total hTERT level was more than
104 copies in the Huh 7 and HLE cell lines, and about 103
copies in the Huh 6–clone 5 cell line. The h-deletion ASV
showed the highest expression of all the hTERT isoforms.
The g-deletion ASV and the combination ASVs of the ag, hg,
and ahg deletion were of very low intensities.
The average telomerase activities in the Huh 6–clone 5,
Huh 7, and HLE cells were 44, 76, and 69 units, respectively.
Discussion
Telomerase is activated in a variety of malignant tumors [25].
Thus, regulation of telomerase activity could be an important
mechanism to limit the growth of cancer cells. Telomerase
activity has been shown to correlate well with the expression
level of hTERT [26–28]. Furthermore, it has been reported
that alternative splicing plays an important role in hTERT
regulation [29,30]. The h-deletion ASV causes premature
translation termination, whereas the a-deletion ASV is 36 bp
and lies within RT motif A, suggesting that it may be a
candidate as a dominant-negative inhibitor of telomerase
[20,21]. The ASVs of the hTERT gene have been reported
not only as deletion types, but also as insertion types. The
insertion types of ASVs are the 38-nucleotide insertion of
intron 4, the partial insertion of intron 11, the 159-nucleotide
insertion of intron 14, and the replacement of the complete
exon 15 and the 5V part of exon 16 with the first 600
nucleotides of intron 14 [12]. Both the a- and g-deletion ASVs
were in-frame deletions, whereas the others were out-of-
framemutations. The novel g-deletion ASVwill cause serious
defects because the g-deletion causes the loss of RT motifs
D and E. Although the authors investigated only a limited
number of hTERT-expressing cell lines, it is possible that the
g-deletion ASV may be a candidate as a dominant-negative
inhibitor of telomerase, along with the a-deletion ASV.
It was clear that the intensity of telomerase activity in HCC
nodules was closely associated with tumor differentiation
[31]. The telomerase activity in well-differentiated HCC tis-
sues was lower than that in poorly differentiated HCC tissues
[32]. The total hTERT mRNA level in Huh 6–clone 5, a well-
differentiated cell line, was one sixth of that in Huh 7, a
differentiated cell line, and one eighth of that in HLE, a
nondifferentiated cell line. In this study, the hTERT expres-
sion in the well-differentiated HCC cell line was also lower
than that in the not well-differentiated HCC cell lines.
In the HCC cell lines, our results complement those of Yi
et al. [33] who described that the h-deletion ASV showed the
highest expression of all the hTERT isoforms. In this study,
the amount of both the h-deletion ASV and the no-deletion
isoform also accounted for more than 80% of the total hTERT
levels. If the g-deletion ASV was a dominant-negative inhib-
itor, the hTERT mRNA that introduced telomerase activity
were both the h-deletion ASV and the no-deletion isoforms.
In this study, there was a statistically significant difference
between the amount of the no-deletion isoform as well as the
h-deletion ASV expression and the telomerase activity
Table 3. Expression and Relative Levels of the hTERT and Alternatively Spliced Isoforms.
Cell lines hTERT mRNA* Telomerasey
No deletion a h g ah ag hg ahg No deletion +h Total hTERT
activity
Huh 6 2.77
(32.5%)
2.23
(9.4%)
2.95
(49.5%)
0.00
(0.0%)
1.98
(5.3%)
0.00
(0.0%)
1.77
(3.3%)
0.00
(0.0%)
3.17
(82.0%)
3.26
(100%)
44
Huh 7 3.28
(13.4%)
1.93
(0.6%)
4.03
(75.9%)
1.79
(0.4%)
3.08
(8.6%)
1.57
(0.3%)
2.06
(0.8%)
0.00
(0.0%)
4.10
(89.3%)
4.15
(100%)
76
HLE 3.29
(18.9%)
2.30
(1.9%)
3.84
(67.7%)
2.32
(2.0%)
2.89
(7.5%)
0.00
(0.0%)
2.04
(1.1%)
1.93
(0.8%)
3.95
(86.6%)
4.01
(100%)
69
LI 90 0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0
HUV-EC-C 0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0.00
(0.0%)
0
Upper row: Each mRNA was calculate as log copies per microgram of total RNA; lower row: relative level of each mRNA was calculated.
*The means of triplicate determinations are shown.
yThe means of duplicate determinations are shown (TPG units).
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(r 2 = 0.983). Thus, researchers who utilize a genetic marker
instead of the telomerase activity [34,35] should measure
both hTERT levels.
Although the g-deletion ASV showed a low expression in
the cell lines with high telomerase activity, this ASV may
occasionally be detected in samples with low telomerase
activity, such as HCC nodules. This ASV was not neces-
sarily specific for tumor cell lines; however, it may have
some roles as a dominant-negative inhibitor, along with the
a-deletion ASV.
While there are still concerns, our results might provide
the basis for more detailed studies on the regulation of
telomerase activity, and may lead to the development of
new cancer therapies. Because this study on the associa-
tions between these ASVs and the clinicopathological fea-
tures have only been developing recently, it will provide
useful information not only for developing prevention strat-
egies for HCC but also for clarifying the biological mecha-
nism of ASVs in human diseases.
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